Cargando…
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
PURPOSE: While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed to investigate the clinical predictors of TRCD in the adjuvant setting of h...
Autores principales: | Kim, Eun Kyoung, Cho, Jinhyun, Kim, Ji-Yeon, Chang, Sung-A, Park, Sung-Ji, Choi, Jin Oh, Lee, Sang Chol, Ahn, Jin Seok, Park, Seung Woo, Im, Young-Hyuck, Jeon, Eun Seok, Park, Yeon Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473274/ https://www.ncbi.nlm.nih.gov/pubmed/30177584 http://dx.doi.org/10.4143/crt.2018.262 |
Ejemplares similares
-
Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction
por: Pi, Seung-Hoon, et al.
Publicado: (2018) -
Effects of Decreased Annular Height and Annular Saddle-Shaped Non-Planarity in Degenerative Severe Mitral Regurgitation with Normal Left Ventricular Ejection Fraction: Real-Time 3D Transesophageal Echocardiography
por: Cho, Eun Jeong, et al.
Publicado: (2017) -
The Extent of Late Gadolinium Enhancement Can Predict Adverse Cardiac Outcomes in Patients with Non-Ischemic Cardiomyopathy with Reduced Left Ventricular Ejection Fraction: A Prospective Observational Study
por: Kim, Eun Kyoung, et al.
Publicado: (2021) -
Comparison of global and regional myocardial strains in patients with heart failure with a preserved ejection fraction vs hypertension vs age-matched control
por: Kim, Hyung Yoon, et al.
Publicado: (2020) -
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
por: Lee, Yong-Pyo, et al.
Publicado: (2022)